NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) on behalf of the company's shareholders.  The investigation seeks to determine whether Stoke Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of Stoke Therapeutics, Inc. and are interested in obtaining additional information about your rights and options, please visit us at: https://pjlfirm.com/ ...

Stoke Therapeutics (STOK) FY Conference August 13, 2025 11:30 AM ET Speaker0Good morning, everyone. I'm Sumant Kulkarni, senior biotechnology analyst for Canaccord Genuity. I'd like to welcome you to our Stokes Therapeutics presentation here today. It's actually not a presentation. It's an interactive Q and A.So please feel free to raise your hands in case you have any questions. You had some really interesting data last night. We'll go into that. But before that, thanks for making it here. We have Ian Smit ...

Stoke Therapeutics (STOK) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Speaker0Good afternoon and welcome to Stokes Therapeutics second quarter twenty twenty five conference call. I'm Tommy Leggett, Chief Financial Officer at Stokes. Joining me for prepared remarks are Ian Smith, our Interim Chief Executive Officer Doctor. Barry Tico, Chief Medical Officer and Doctor. Kimberly Parkerson, Head of Neurology Clinical Development.In addition, Jason Hoyt, our Chief Patient Officer will participate in Q and ...

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is developing zorevunersen as a potential disease-modifying medicine for Dravet syndrome [16] - Initial 70mg doses of zorevunersen demonstrated substantial and sustained reductions in convulsive seizure frequency [18] - Ongoing zorevunersen treatment showed substantial and durable reductions in major motor seizure frequency in OLE studies [21] - 36-month OLE data shows continuing improvements in cognition and behavior with zorevunersen treatment [56] - The EMPEROR Phase 3 study is designed to assess disease modification in Dravet syndrome with a dosing regimen of 2x70mg followed by 2x45mg over a 52-week treatment period [31, 32] - The EMPEROR Phase 3 study has dosed its first patient in August 2025 and anticipates data in 2H 2027, randomizing approximately 170 patients across ~70 global sites [35] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - Approximately 65-90% of ADOA cases are caused by mutations in one allele of the OPA1 gene, leading to haploinsufficiency [64] - Up to 46% of ADOA patients are registered as legally blind [65] - Preclinical findings support further development of STK-002, showing increased OPA1 protein and ATP-linked respiration [70] - A Phase 1 study of STK-002 in ADOA patients is underway in the UK, involving 21 patients aged ≥18 to <55 years receiving single ascending doses (0.1, 0.3, 0.5, & 0.7 mg/eye) [76]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38938 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...

EX 99.1 – Webcast and conference call for analysts and investors at 4:30PM Eastern Time today – BEDFORD, Mass., August 12, 2025 – Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter end ...

Core Insights - The analysis of the Phase 3 zorevunersen dosing regimen indicates improvements in cognition and behavior at Week 68, supporting its potential as a disease-modifying treatment for Dravet syndrome [1][2][4] - Zorevunersen has shown substantial and durable reductions in major motor seizure frequency and improvements in cognitive and behavioral measures over two years of treatment [2][4] - The Phase 3 EMPEROR study will assess key secondary endpoints related to cognition and behavior, which are critical for evaluating the treatment's effectiveness [3][5] Company Overview - Biogen Inc. and Stoke Therapeutics are collaborating on the development of zorevunersen, an investigational therapy aimed at addressing the underlying causes of Dravet syndrome [1][8] - Stoke Therapeutics focuses on restoring protein expression through RNA medicine, with zorevunersen being their first medicine in development [9] - Biogen is a leading biotechnology company that aims to deliver innovative treatments and create value for shareholders [10] Disease Context - Dravet syndrome is a severe neurodevelopmental disorder characterized by recurrent seizures and significant cognitive and behavioral impairments, affecting an estimated 38,000 individuals in the U.S., UK, EU-4, and Japan [3][7] - The condition is primarily caused by mutations in the SCN1A gene, leading to insufficient NaV1.1 protein levels in neuronal cells [7][8] - Current treatments primarily focus on seizure control, with no approved therapies addressing the cognitive and behavioral aspects of the disease [3][7] Clinical Study Insights - The Phase 3 EMPEROR study is designed to evaluate the effects of zorevunersen on cognition and behavior, with a focus on five sub-domains of the Vineland-3 Adaptive Behavior Scales [5][6] - The dosing regimen includes two loading doses of 70mg followed by maintenance doses of 45mg, which has shown promising results in previous studies [4][5] - The analysis utilized a mixed-effects model for repeated measures to assess the potential effects of the dosing regimen on patient outcomes [4]

Stoke Therapeutics (STOK) 2025 Conference June 04, 2025 01:25 PM ET Speaker0 Yeah. I mean, it truly does differentiate your medicine. Speaker1 Right. Are you ready? Yep. Okay. We're gonna get started with our next session. I'm Andrew Tsai, senior biotech analyst at Jefferies. Thanks for joining me today. It's my pleasure to have Stokes Interim CEO, Ian Smith, by my side today. Welcome, Ian. Speaker0 Thank you, Andrew. Speaker1 Thank you. Yep. And so maybe spend the next couple minutes discussing Stokes, wha ...

Core Viewpoint - Stoke Therapeutics, Inc. (STOK) has shown a significant price increase of 25.2% over the past four weeks, with a mean price target of $22.38 indicating a potential upside of 132.4% from the current price of $9.63 [1] Price Targets and Analyst Consensus - The average price target for STOK ranges from a low of $15 to a high of $35, with a standard deviation of $6.82, suggesting variability in analyst estimates [2] - The lowest estimate indicates a potential increase of 55.8%, while the most optimistic estimate points to a 263.5% upside [2] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising STOK's earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 59.1% over the past month, with three estimates going higher and no negative revisions [12] - STOK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38938 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisd ...